Repositioning Candidate Details
| Candidate ID: | R0940 |
| Source ID: | DB06200 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Tedisamil |
| Synonyms: | Tedisamil |
| Molecular Formula: | C19H32N2 |
| SMILES: | C(C1CC1)N1CC2CN(CC3CC3)CC(C1)C21CCCC1 |
| Structure: |
|
| DrugBank Description: | Tedisamil (planned trade name Pulzium) is an investigational drug for atrial fibrillation and atrial flutter. It is currently being developed by Solvay and is currently under regulatory review by the United States Food and Drug Administration. |
| CAS Number: | 90961-53-8 |
| Molecular Weight: | 288.4708 |
| DrugBank Indication: | Investigated for use/treatment in arrhythmia, atrial fibrillation, and angina. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | It is hypothesized tedisamil prevents Ca2+ overload by the cAMP dependent SR Ca2+ uptake . |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |